All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub
Brought to you by Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EBMT 2023

Share:

Apr 25, 2023

X post image

10 May 2023

KEY POINTS

#EBMT23 | Ide-cel vs SoC in triple exposed RRMM
▪️ PFS: 13.3 months vs 4.4 months in ide-cel and SoC, respectively
▪️ ORR: 71% (39% CR) vs 42% (5% CR) in ide-cel and SoC, respectively
▪️ Risk of disease progression or death 51% lower with ide-cel

View on 

X post image

28 Apr 2023

#EBMT23 is now over! We hope you’ve enjoyed keeping up with our live updates!

Keep an eye on @MM_Hub for post-congress articles and interviews with key experts.

#mmsm #myeloma

View on 

X post image

26 Apr 2023

CONGRESS|#EBMT23 Hani Hassoun @MSKCancerCenter discusses the DETERMINATION trial evaluating RVd alone vs RVd+ASCT. Results suggest select differential outcomes across subgroups and show differential impact of prognostic factors between treatment approaches #multiplemyeloma #MMsm

View on 

X post image

26 Apr 2023

CONGRESS|#EBMT23 @amarkelkar discusses a state-transition microsimulation model to simulate outcomes and costs associated with therapy for patients with MM in subsequent relapses. The model demonstrated marginal improved QALYs with RVd+ASCT #multiplemyeloma #MMsm #medicalcongress

View on 

X post image

26 Apr 2023

CONGRESS|#EBMT23 @mbeksac56 evaluates the CIBMTR, GIMEMA, and EBMT scoring systems to predict early relapse in #multiplemyeloma. Validation showed EBMT is a reliable tool that recognises very low and very high-risk patients at the time of AHCT #MMsm #medicalcongress

View on 

X post image

26 Apr 2023

CONGRESS|#EBMT23 Sarita Jaiswal presents results from a study on abatacept and IL-15 induced haploidentical NK cell based immunotherapy following AHCT in HRMM. All patients achieved a CR at D+100. 2 patients had relapsed at 9 and 24 months #multiplemyeloma #MMsm #medicalcongress

View on 

X post image

26 Apr 2023

CONGRESS|#EBMT23 Tessa Kerre @uzgent presents an 18-month follow up from cohort B of the CARTITUDE-2 trial investigating cilta-cel. Overall response rate was 100% and median time to best response was 5.1 months. 93% of patients achieved MRD 10-5 negativity #multiplemyeloma #MMsm

View on 

X post image

26 Apr 2023

CONGRESS|#EBMT23 @mvmateos presents updated results from the CARTITUDE-2 trial evaluating cilta-cel in patients with previous exposure to non-cellular anti-BCMA immunotherapy. Median DOR was 12.8 months and median PFS was 9.1 months #multiplemyeloma #MMsm #medicalcongress

View on 

X post image

24 Apr 2023

CONGRESS #EBMT23 | @paurotero @ClinicaNavarra present the KARMMA-3 a phase III trial of ide-cel in triple class exposed pts with R/R MM. N=386. Ide-cel improved PFS (median 13.3 vs 4.4 months; P <0.0001) & ORR (71% vs 42%; P <0.0001) vs standard regimens #myeloma #mmsm

View on 

X post image

24 Apr 2023

The @MM_Hub is covering the 49th Annual Meeting of the EBMT.

📅 Date: April 23–26
📍 Location: Paris and online

Look out on our socials for live coverage during the day from our virtual and in-person attendance!

#EBMT #medicalcongress #lymsm #EBMT23

View on 

X post image

17 Apr 2023

The @MM_Hub will be covering the 49th Annual Meeting of the EBMT.

Date: April 23–26

Location: Paris, France and online

Keep an eye on our socials for live coverage throughout the congress!

#EBMT23 #mmsm

View on 

<span>&nbsp;</span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EBMT 2023European Society for Blood and Marrow Transplantation

Your opinion matters

Regarding bispecific antibodies for multiple myeloma, which of the following do you consider the biggest hurdle for patients and caregivers?

Newsletter

Subscribe to get the best content delivered to your inbox